- Trials with a EudraCT protocol (4,502)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4,502 result(s) found for: MRI.
Displaying page 1 of 226.
| EudraCT Number: 2019-001599-12 | Sponsor Protocol Number: ASC-Man-P016 | Start Date*: 2019-10-21 | |||||||||||
| Sponsor Name:Ascelia Pharma AB | |||||||||||||
| Full Title: A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment | |||||||||||||
| Medical condition: MRI in terms of visualization of detected focal liver lesions in patients with known or Suspected focal liver lesions and severe renal impairment | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) SE (Ongoing) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000939-41 | Sponsor Protocol Number: PET/MRI_Gliom_FACBC | Start Date*: 2016-05-03 |
| Sponsor Name:Anna Karlberg | ||
| Full Title: Diagnostic assessment of 18F-fluciclovine (FACBC) - PET/MRI in the evaluation of suspected cerebral gliomas | ||
| Medical condition: Gliomas | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001619-37 | Sponsor Protocol Number: 48895 | Start Date*: 2014-07-14 |
| Sponsor Name:Maastricht University Medical Centre | ||
| Full Title: Contrast enhanced Diffusion-weighted Magnetic Resonance Imaging for detection of pathologic lymph nodes in ovarian cancer – a feasibility study. | ||
| Medical condition: Ovarian Cancer - diagnosis of lymph nodes | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-003133-18 | Sponsor Protocol Number: NL.58570.091.16 | Start Date*: 2017-01-19 |
| Sponsor Name:radboudumc | ||
| Full Title: Preoperative staging by combidex MRI in patients with resectable esophageal carcinoma, a feasibility study | ||
| Medical condition: Detection of locoregional lymph node metastases in patients with resectable esophageal carcinoma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-001281-13 | Sponsor Protocol Number: KS-2004-06-SET | Start Date*: 2005-11-15 |
| Sponsor Name:DSC Services, s.r.o. | ||
| Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study) | ||
| Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002588-32 | Sponsor Protocol Number: 7TNANO2 | Start Date*: 2016-09-15 |
| Sponsor Name:Radboudumc | ||
| Full Title: USPIO- enhanced High Field MRI for restaging lymph node status in rectal cancer: an explorative study | ||
| Medical condition: Lymph node metastases in rectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003988-54 | Sponsor Protocol Number: GDX-44-010 | Start Date*: 2019-07-03 | ||||||||||||||||
| Sponsor Name:Guerbet | ||||||||||||||||||
| Full Title: Efficacy and Safety of gadoPIClenol for CenTral NervoUs System (CNS) Magnetic REsonance Imaging (MRI) | ||||||||||||||||||
| Medical condition: Patient presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (e.g., primary and secondary tumors) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-005917-35 | Sponsor Protocol Number: CMC-P014 | Start Date*: 2012-03-20 | |||||||||||
| Sponsor Name:CMC Contrast AB | |||||||||||||
| Full Title: Accuracy in Diagnosis of Focal Liver Lesions following Oral Administration of CMC-001 Combined with Diffusion Weighted Magnetic Resonance Imaging (MRI) of the Liver. An Open-Label, Non-Randomised, ... | |||||||||||||
| Medical condition: Focal Liver Lesions in Diagnosed Cancer Patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-013081-17 | Sponsor Protocol Number: BAY 86-6661/91784 (312046) | Start Date*: 2009-11-20 | |||||||||||
| Sponsor Name:Bayer HealthCare Pharmaceuticals, Inc. | |||||||||||||
| Full Title: Open-label, multi-center, two-stage, age stratified, pharmacokinetic, safety, and efficacy study in children 2 month to < 2 years of age undergoing Magnevist Injection enhanced MRI | |||||||||||||
| Medical condition: Contrast-enhanced MRI in children 2 month to < 2 years | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003946-18 | Sponsor Protocol Number: GDX-44-011 | Start Date*: 2019-05-03 | |||||||||||
| Sponsor Name:GUERBET | |||||||||||||
| Full Title: Efficacy and safety of gadopiclenol for body magnetic resonance imaging (MRI) | |||||||||||||
| Medical condition: Patients presenting with know or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region among head & neck, thorax (including breast), abdomen (including liver, pancreas a... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) HU (Completed) BG (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004037-93 | Sponsor Protocol Number: TRACE | Start Date*: 2018-01-17 |
| Sponsor Name:Afdeling for Rygkirurgi, Led- og Bindevævssygdomme ; Rigshospitalet - Glostrup | ||
| Full Title: TReat-to-tArget (T2T) with seCukinumab in axial spondyloarthritis. IdEntification of MRI and biochemical biomarkers for disease activity, treatment response and structural damage progression (the T... | ||
| Medical condition: Axial spondyloarthritis and ankylosing spondylitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003779-32 | Sponsor Protocol Number: NL77171.091.21 | Start Date*: 2021-09-27 |
| Sponsor Name:Radboud University Medical Center | ||
| Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study). | ||
| Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-003699-38 | Sponsor Protocol Number: CEDM-MRI | Start Date*: 2021-04-28 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
| Full Title: DETECTION RATE AND CLASSIFICATION OF BREAST LESIONS WITH DIGITAL MAMMOGRAPHY WITH CONTRAST MEDIUM (CEDM) ALONE AND IN COMBINATION WITH TOMOSYNTHESIS COMPARED TO MR IMAGING WITH GADOLINIUM IN DYNAMI... | |||||||||||||
| Medical condition: Breast souspicious lesions | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000583-16 | Sponsor Protocol Number: 312041 | Start Date*: 2009-03-13 | |||||||||||
| Sponsor Name:Bayer Schering Pharma AG (BSP) | |||||||||||||
| Full Title: Multi-center, randomized comparison study to eVALUatE outcomes and resource needs of imaging and treatment following Primovist-enhanced MRI of the liver in comparison to extracellular contrast medi... | |||||||||||||
| Medical condition: Patients with history of colorectal cancer and known or suspected metachronous liver metastasis(es) scheduled to undergo contrast-enhanced tomographic imaging (i.e. CE-MRI or CE-CT) of the liver | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) SE (Completed) NL (Completed) ES (Completed) IT (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002168-14 | Sponsor Protocol Number: nano-MRI.H&N.1 | Start Date*: 2019-02-12 |
| Sponsor Name:Radboudumc | ||
| Full Title: Validation of USPIO-enhanced MRI for detection of lymph node metastases in head and neck carcinoma: a pilot study. | ||
| Medical condition: Lymph node metastases in patients with squamous cell head and neck carcinoma. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-005011-17 | Sponsor Protocol Number: 7TNANO1 | Start Date*: 2015-02-24 |
| Sponsor Name:Radboudumc | ||
| Full Title: Nano MRI on 7 Tesla: A technical validation study in rectal and breast cancer | ||
| Medical condition: Lymph node metastases in rectal cancer, breast cancer and cancer in general | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-005249-13 | Sponsor Protocol Number: Primovist - OATP1B1 | Start Date*: 2007-01-31 | |||||||||||
| Sponsor Name:Department of Clinical Pharmacology, University of Greifswald | |||||||||||||
| Full Title: Influence of the OATP1B1 genotype on the hepatic uptake of Primovist® in healthy volunteers and in patients with liver disease | |||||||||||||
| Medical condition: The trial will be performed in 32 healthy subjects and in 60 patients with a liver disease subjected to MR imaging | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-011824-79 | Sponsor Protocol Number: 91686125 | Start Date*: 2009-11-03 | |||||||||||
| Sponsor Name:Academic Medical Center | |||||||||||||
| Full Title: Effects of fluoxetine on the outgrowth of the serotonergic system | |||||||||||||
| Medical condition: We investigate whether the effects fluoxetine (Prozac®) on the outgrowth of the serotonergic system are dependent on age. In a 16 week multicenter randomized, double-blind, placebo controlled trial... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000724-10 | Sponsor Protocol Number: 60978 | Start Date*: 2018-07-04 |
| Sponsor Name:Academic Medical Center | ||
| Full Title: Targeting esophageal cancer with HDL nanoparticles: an imaging study | ||
| Medical condition: Primary esophageal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-012218-30 | Sponsor Protocol Number: ML22648 | Start Date*: 2009-10-06 |
| Sponsor Name:Roche Farmacêutica Química, Lda. | ||
| Full Title: A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 w... | ||
| Medical condition: Men and women > 18 years of age with RA who are currently experiencing an inadequate clinical response to a stable dose of non-biologic DMARDs (at least 12 weeks) and with MRI documented synovitis ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: PT (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.